---
figid: PMC3246694__DRP2012-259170.002
figlink: /pmc/articles/PMC3246694/figure/fig2/
number: Figure 2
caption: Representation of the resistance mechanisms to the vemurafenib. (a) Vemurafenib
  causes cell death by inhibiting V600E BRAF kinase activity and signaling transduction
  through the MAPK pathway. (b) New mutations in the NRAS causes heterodimerization
  of BRAF/CRAF and reactivation of the signaling pathway. (c) and (d) Phosphorylation
  of ERK independent of RAF stimulation is the result of the overexpression of COT
  (c) and of the additional mutation in MEK kinase (d). (e) Overexpression of PDGFRβ
  can lead to resistance to vemurafenib treatment independent from the continuous
  inhibition of the MAPK pathway.
pmcid: PMC3246694
papertitle: 'Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the
  Treatment of Metastatic Malignant Melanoma.'
reftext: Felipe Ades, et al. Dermatol Res Pract. 2012;2012:259170.
pmc_ranked_result_index: '44525'
pathway_score: 0.9141838
filename: DRP2012-259170.002.jpg
figtitle: Representation of the resistance mechanisms to the vemurafenib
year: '2012'
organisms: Homo sapiens
ndex: 4c6b6729-df0c-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3246694__DRP2012-259170.002.html
  '@type': Dataset
  description: Representation of the resistance mechanisms to the vemurafenib. (a)
    Vemurafenib causes cell death by inhibiting V600E BRAF kinase activity and signaling
    transduction through the MAPK pathway. (b) New mutations in the NRAS causes heterodimerization
    of BRAF/CRAF and reactivation of the signaling pathway. (c) and (d) Phosphorylation
    of ERK independent of RAF stimulation is the result of the overexpression of COT
    (c) and of the additional mutation in MEK kinase (d). (e) Overexpression of PDGFRβ
    can lead to resistance to vemurafenib treatment independent from the continuous
    inhibition of the MAPK pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RAF1
  - KRAS
  - NRAS
  - MAP2K2
  - MAP2K1
  - BRAF
  - HRAS
  - CROT
  - MAPK1
  - MAPK3
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
genes:
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: NRAS
  symbol: NRAS
  source: hgnc_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: COT
  symbol: COT
  source: hgnc_alias_symbol
  hgnc_symbol: CROT
  entrez: '54677'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
